It is best to seek treatment for cutaneous squamous cell carcinoma (cSCC) as early as possible, as doctors can usually treat early stage cSCC easily and locally. Delays in treatment could mean cancer ...

Comparing metagenomic profiles of the skin microbiome in immunosuppressed patients and those at high and low risk for cutaneous squamous cell carcinoma (SCC) revealed distinct expansions in fungal and ...

Ruxolitinib (a JAK2 inhibitor) and belumosudil (a ROCK2 inhibitor) have recently been approved by the Food and Drug Administration (FDA) for the treatment of chronic graft-versus-host disease (GVHD).

Mohs surgery was associated with improved outcomes compared with wide local excision (WLE) in patients with primary high-stage cutaneous squamous cell carcinoma (cSCC), showing lower rates of ...

A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the first ...